Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4215442 | 0.99 | MAPK14 (0.76) | MAPK14MAPK13 | |
| SCHEMBL13745181 | 0.89 | MAPK14 (0.61) | MAPK14MAPK13 | |
| Hydrochloric Acid SCHEMBL4218000 | 0.88 | MAPK14 (0.62) | MAPK14MAPK13 | |
| SCHEMBL13745251 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13 | |
| Hydrochloric Acid SCHEMBL4217990 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL5795573 | 0.84 | MAPK14 (0.78) | MAPK14MAPK13 | |
| SCHEMBL5765908 | 0.81 | MAPK14 (0.73) | MAPK14MAPK13 | |
| SCHEMBL5765074 | 0.80 | MAPK14 (0.72) | MAPK14MAPK13 | |
| SCHEMBL5763350 | 0.77 | MAPK14 (0.68) | MAPK14MAPK13 | |
| SCHEMBL5765247 | 0.76 | MAPK14 (0.73) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209577-A1 | Novel Triazolopyridine Compounds | MAP3K2, MAP3K5, MAP3K9 | MAPK14 126/4885MAPK13 113/4885 |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | TNF, MAP3K2, MAP3K5 | MAPK14 160/4885MAPK13 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.